"The rising demand (within Russia) for healthcare has given a huge boost to the pharmaceuticals sector, and has revived the sectors of clinical trials, biotechnology and medical devices. The pharmaceuticals sector was worth U.S.$16.40 billion in 2010 and its compound annual growth rate (CAGR) during 2004-2014 is likely to be 13.9 per cent..............Meanwhile, the biotechnology sector was valued at U.S.$1.60 billion in 2010 and is poised to perform even better" - Frost & Sullivan, April 2011

"The government will......channel over 120 billion roubles (U.S.$4.3 billion) to modernise the  national pharmaceutical and medical equipment industries and to build up  technology reserves, under a new federal programme until 2020. The plan is to  establish 17 research centres to develop new drugs and design medical equipment.  In 2010 alone, Russian and foreign companies invested over 40 billion roubles (U.S.$1.4 billion) to  develop the production of pharmaceuticals and medical equipment" - Prime Minister Vladimir Putin, Address to State Duma, 20 April 2011

"The Russian pharmaceutical market is import oriented. (Some) 78 per cent of drugs in money terms consumed by the population, are produced abroad.............(The) Drug import volume in 2010 amounted to U.S.$11.8 billion, which is 28 per cent higher than in 2009...........DSM forecast (that) the Russian pharmaceutical market will grow in 2011 by 12 per cent in roubles and will reach about 750 billion roubles (U.S.$26.7 billion)" - DSM Group, Moscow, 2011 

Biopharm Analytica offers a range of bespoke consulting and research services with regard to the bioscience and pharmaceutical sectors in Russia and the Newly Independent States. The UK-based company has undertaken market surveys for leading biotechnology multinationals and completed studies of niche technologies and markets. To discuss your detailed requirements with one of our analysts please call +44 (0)121 2702854 .

Biopharm Analytica also provides access to an independent English language online business news and information service focusing on developments in biotechnology and the pharmaceutical industry in Russia and the Newly Independent States (NIS). One of its key focuses is on the identification of potential opportunities for international companies with a strong emphasis on high-value projects. Coverage is also provided of ongoing pharmaceutical and biotech R & D and manufacturing within the region. Subscription to Biopharm Analytica by registered users, will allow immediate and privileged access to the information service covering major news stories impacting upon the biotechnology and pharmaceutical sectors in Russia and the NIS. A major searchable on-line database of news reports covering the period 2004-2012, providing an invaluable source of business intelligence with regard to the Russian biopharmaceutical sector, is available only to subscribers. It is anticipated that Biopharm Analytica's news service will rapidly become an indispensable adjunct to those companies and analysts seeking real-time news and information focused on the Russian and NIS biotechnology and pharmaceutical sectors. Credit card payments are accepted using encrypted electronic card processing facilities provided by HSBC. To discuss your subscription requirements with one of our sales staff please call +44 (0)121 2702854 .

© Biopharm Analytica Limited 2012. All Rights Reserved. This site is owned and operated by Biopharm Analytica Limited. Registered Office: Suite B, 29 Harley Street, London, W1G 9QR. Registered in England and Wales. Reg. No. 5360763. VAT Reg. No. 930 3219 57.